Interview with Marisa Sanvito, Senior Director, Quintiles Brazil
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ
Tel: (21) 2159-2600
Web: http://www.bago.com.br/web/cgi/cgilua.exe/sys/start.htm?tpl=home
With an innovative profile, Bagó Group is a leader in healthcare in Latin America. It is formed by a pool of solid enterprises, oriented around healthcare and improving quality of life.
Proud to be Latin American, the group was founded in 1934 in Argentina, and today is one of the most significant in the world pharmaceutical market. With an outstanding presence in Latin America and extending its roots over the world, it counts on over 6500 employees that share the same values of innovation and the same ideals of growth.
Laboratórios Bagó was established in Brazil in 2002, with the aim of working in the pharmaceutical industry as a tool for building a strong laboratory, and now counts a multidisciplinary team composed by over 180 professionals.
It is an intellectual leader, a reference in the Marketing business and has worked with Merck, Glaxo and Roche Laboratories.
Hydrophilic Array, Trifamox IBL, Magnesium Valproate, Alprazolam Sublingual, Talniflumate
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
See our Cookie Privacy Policy Here